uploads/2018/06/Graph-6-2-1.png

Commercial Launch of NexSys PCS May Boost Haemonetics’s Revenues

By

Updated

NexSys PCS FDA clearance

On March 28, 2018, the FDA approved an enhancement to Haemonetics’s (HAE) NexSys PCS embedded software, which will activate a yield-enhancing solution based on YES technology to improve the total plasma yield per collection. While the NexSys PCS device was already approved by the FDA in July 2017, the recent approval has enabled the company to initiate discussions with customers about the value proposition of its integrated plasma collection platform consisting of NexSys PCS, NesLynk DMS Donor Management Software, other disposables, and technical support services.

Plasma donor center experience programs

Haemonetics is also involved in plasma donor center experience programs that involve the use of NexSys PCS device and YES technology. These programs have helped highlight the importance of the integrated and paperless plasma collection system. These centers enable customers to better understand implications of the YES technology not only for plasma collection but also for plasma fractionation. Haemonetics is also working with these customers to help them understand the protocols and the standard operating procedures that have to be followed while operating these devices. The plasma donor center experience programs are thus expected to play a pivotal role in converting the donor centers to the new systems.

In the next article, we’ll discuss growth prospects for Haemonetics’ blood center business in greater detail.

More From Market Realist